Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Methods (San Diego, Calif.)|April 26, 2005
Design of humanized antibodies: from anti-Tac to ZenapaxNaoya Tsurushita, Paul R Hinton, Shankar KumarJournal of Immunology (Baltimore, Md. : 1950)|December 21, 2005
An engineered human IgG1 antibody with longer serum half-lifePaul R Hinton, Joanna M Xiong, Mary G Johlfs, et al.Protein Engineering, Design & Selection : PEDS|July 30, 2020
Design, creation and in vitro testing of a reduced immunogenicity humanized anti-CD25 monoclonal antibody that retains functional activityMarcia Stickler, Anita Reddy, Joanna M Xiong, et al.Experimental Hematology|September 16, 2025
An engineered IgM antibody targeting CD20 has enhanced complement-dependent cytotoxicity compared with an IgGKevin C Hart, Paul R Hinton, Marigold Manlusoc, et al.The Journal of Biological Chemistry|December 31, 2003
Engineered human IgG antibodies with longer serum half-lives in primatesPaul R Hinton, Mary G Johlfs, Joanna M Xiong, et al.Mabs|July 2, 2016
The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®Bishu Ganguly, Balaji Balasa, Lyubov Efros, et al.Nature|June 3, 2021
Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variantsZhiqiang Ku, Xuping Xie, Paul R Hinton, et al.Emerging Microbes & Infections|December 11, 2023
An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoVHailong Guo, Bomsoo Cho, Paul R Hinton, et al.Pageof 1